Why the study?
Since obesity may decrease exemestane efficacy, this study analyzed changes in sex steroids, adipokines, Ki-67, and drug levels in relation to obesity across alternative dosing regimens.
Does alternative dosing of exemestane (three times weekly or once weekly) maintain biomarker modulation compared to daily dosing in postmenopausal women with ER-positive breast cancer, particularly in relation to obesity?
Population
Postmenopausal women with early-stage ER-positive breast cancer
Comparison
Exemestane 25 mg QD vs 25 mg TIW vs 25 mg QW
Design
3-arm randomized presurgical trial
Follow-up
4–6 weeks
Authors
Loading...
Thrice-weekly exemestane maintains estradiol suppression in obese ER+ patients; challenges full biomarker equivalence on estrone and Ki-67.
Does alternative dosing of exemestane (three times weekly or once weekly) maintain biomarker modulation compared to daily dosing in postmenopausal women with ER-positive breast cancer, particularly in relation to obesity?
Exemestane 25 mg three times weekly maintains comparable estradiol suppression to daily dosing in obese postmenopausal women with ER-positive breast cancer, though with less suppression of estrone and Ki-67.
Johansson et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: